Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

S1PR5 regulates NK cell responses in preventing graft-versus-host disease while preserving graft-versus-tumour activity in a murine allogeneic haematopoietic stem cell transplantation model.

Wang F, Zhao S, Gu Z, Zhao X, Yang N, Guan L, Liu T, Wang L, Fang S, Zhu C, Luo L, Li M, Wang L, Gao C.

Hematol Oncol. 2019 Aug 29. doi: 10.1002/hon.2669. [Epub ahead of print]

PMID:
31465552
2.

[Influence of NK cell S1PR5 expression on graft versus host disease in allogeneic hematopoietic stem cell transplantation].

Guan LX, Cai B, Gao L, Li XH, Li M, Wang LL, Gao CJ.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Apr;20(2):412-5. Chinese.

PMID:
22541110
3.

Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.

Lu SX, Kappel LW, Charbonneau-Allard AM, Atallah R, Holland AM, Turbide C, Hubbard VM, Rotolo JA, Smith M, Suh D, King C, Rao UK, Yim N, Bautista JL, Jenq RR, Penack O, Na IK, Liu C, Murphy G, Alpdogan O, Blumberg RS, Macian F, Holmes KV, Beauchemin N, van den Brink MR.

PLoS One. 2011;6(7):e21611. doi: 10.1371/journal.pone.0021611. Epub 2011 Jul 6.

4.

Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.

Chen G, Wu D, Wang Y, Cen J, Feng Y, Sun A, Tang X, Chang H, Zhu Z.

Eur J Haematol. 2008 Sep;81(3):226-35. doi: 10.1111/j.1600-0609.2008.01108.x. Epub 2008 Jun 28.

PMID:
18573173
5.

NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT.

Karimi MA, Bryson JL, Richman LP, Fesnak AD, Leichner TM, Satake A, Vonderheide RH, Raulet DH, Reshef R, Kambayashi T.

Blood. 2015 Jun 4;125(23):3655-63. doi: 10.1182/blood-2015-02-629006. Epub 2015 Mar 18.

6.
7.

Recombinant IL-7/HGFβ hybrid cytokine separates acute graft-versus-host-disease from graft-versus-tumour activity by altering donor T cell trafficking.

Hu R, Liu Y, Song Y, Su M, Lu X, Rood D, Lai L.

Br J Haematol. 2016 Nov;175(3):505-516. doi: 10.1111/bjh.14268. Epub 2016 Jul 22.

PMID:
27447780
8.

Identification and characterization of the specific murine NK cell subset supporting graft-versus-leukemia- and reducing graft-versus-host-effects.

Meinhardt K, Kroeger I, Bauer R, Ganss F, Ovsiy I, Rothamer J, Büttner M, Atreya I, Waldner M, Bittrich M, Lehmann CH, Rieger MA, Beilhack A, Zeiser R, Edinger M, Dudziak D, Mackensen A, Rehli M, Ullrich E.

Oncoimmunology. 2015 Feb 3;4(1):e981483. eCollection 2015 Jan.

10.

Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation.

Kim SY, Lee H, Han MS, Shim H, Eom HS, Park B, Kong SY.

Clin Lymphoma Myeloma Leuk. 2016 Sep;16(9):527-535.e2. doi: 10.1016/j.clml.2016.06.013. Epub 2016 Jun 8.

PMID:
27375156
11.

Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.

Holtick U, Albrecht M, Chemnitz JM, Theurich S, Skoetz N, Scheid C, von Bergwelt-Baildon M.

Cochrane Database Syst Rev. 2014 Apr 20;(4):CD010189. doi: 10.1002/14651858.CD010189.pub2. Review.

PMID:
24748537
12.

Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma.

Verneris MR, Ito M, Baker J, Arshi A, Negrin RS, Shizuru JA.

Biol Blood Marrow Transplant. 2001;7(10):532-42.

13.

Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.

Lee DA, Denman CJ, Rondon G, Woodworth G, Chen J, Fisher T, Kaur I, Fernandez-Vina M, Cao K, Ciurea S, Shpall EJ, Champlin RE.

Biol Blood Marrow Transplant. 2016 Jul;22(7):1290-1298. doi: 10.1016/j.bbmt.2016.04.009. Epub 2016 Apr 16.

14.

[Experimental study on IL-2- and IL-15 application in allogeneic hematopoietic stem cell transplantation].

Chen GH, Wu DP, Sun AN, Yang MZ, Wang Y, Tang XW, Chang HR, Feng YF, Zhu ZL.

Zhonghua Xue Ye Xue Za Zhi. 2008 Aug;29(8):526-30. Chinese.

PMID:
19112915
15.

Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.

Ueha S, Yokochi S, Ishiwata Y, Kosugi-Kanaya M, Shono Y, Shibayama S, Ito S, Matsushima K.

Cancer Sci. 2017 Oct;108(10):1967-1973. doi: 10.1111/cas.13346. Epub 2017 Aug 29.

16.

Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms.

Murashige N, Kami M, Kishi Y, Kim SW, Takeuchi M, Matsue K, Kanda Y, Hirokawa M, Kawabata Y, Matsumura T, Kusumi E, Hirabayashi N, Nagafuji K, Suzuki R, Takeuchi K, Oshimi K.

Br J Haematol. 2005 Aug;130(4):561-7.

PMID:
16098071
17.

NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects.

Olson JA, Leveson-Gower DB, Gill S, Baker J, Beilhack A, Negrin RS.

Blood. 2010 May 27;115(21):4293-301. doi: 10.1182/blood-2009-05-222190. Epub 2010 Mar 16.

18.

Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation.

Simonetta F, Alvarez M, Negrin RS.

Front Immunol. 2017 Apr 25;8:465. doi: 10.3389/fimmu.2017.00465. eCollection 2017. Review.

19.

[Role of alloreactive natural killer cell in mouse MHC haploidentical bone marrow transplantation].

He Y, Wang HH, Wang M, Zhou Z, Zhai WJ, Huang Y, Jiang EL, Wang ZD, Zhou SY, Liu QG, Feng SZ, Han MZ.

Zhonghua Xue Ye Xue Za Zhi. 2006 Feb;27(2):82-6. Chinese.

PMID:
16732957
20.

Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.

Choi J, Cooper ML, Alahmari B, Ritchey J, Collins L, Holt M, DiPersio JF.

PLoS One. 2014 Oct 7;9(10):e109799. doi: 10.1371/journal.pone.0109799. eCollection 2014.

Supplemental Content

Support Center